YAbS







Remternetug Clinical Naked monospecific

Antibody Information

Entry ID 954
INN Remternetug
Status Clinical
Drug code(s) LY3372993
Brand name None
mAb sequence source mAb human
General Molecular Category Naked monospecific
Format, general category Full length Ab
Format details None
Isotype (Fc) IgG1
Light chain isotype kappa
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology None

Therapeutic information

Target(s) Amyloid beta (N3pG)
Indications of clinical studies Alzheimer disease
Primary therapeutic area Neurological disorders

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Phase 3
Status Active
Start of clinical phase (IND filing or first Phase 1) November 15, 2018
Start of Phase 2
Start of Phase 3 August 01, 2022
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company Eli Lilly and Company
Licensee/Partner None
Comments about company or candidate NCT06653153 Phase 3 in AD due to start in Oct 2024.
NCT06647498 Phase 2/3 in AD due to start in Nov 2024.
NCT05463731 Phase 3 started in Aug 2022 is recruiting as of last update on May 17, 2023.
NCT04451408 Phase 1 started in July 2020; NCT03720548 Phase 1 started in Nov 2018.
Full address of company Indianapolis, Indiana, United States
North America
United States of America
https://www.lilly.com/contact-us

Description/comment

Described as a monoclonal antibody in: Cummings, J., Lee, G., Ritter, A., Sabbagh, M., Zhong, K. (2019). Alzheimer's Disease Drug Development
Pipeline: 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 5 272-293. Elsevier.
http://dx.doi.org/10.1016/j.trci.2019.05.008
Remternetug (LY3372993) is an IgG1 monoclonal antibody directed
at the pyroglutamate modification of the third amino acid of
amyloid-beta peptide that is present only in brain amyloid plaques
https://assets.ctfassets.net/mpejy6umgthp/51Sv0wOrFxfiHJNqcyuNYu/0c5df804e8a23256262fcb40489ae181/REMIPT3_ADPD2023_JIN_SAFETY_PLAQUE_REDUCTION_Ph1LAKB.pdf

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None